Valproate activates phosphodiesterase-mediated cAMP degradation: Relevance to C6 glioma G1 phase progression

Neurotoxicology and Teratology

Volumn 26, Issue 1, 2004, Pages 73-81

  Gallagher, Helen C ^a   Bacon, Christopher L ^a   Odumeru, Oladapo A ^a   Gallagher, Kevin F ^a   Fitzpatrick, Thérèse ^a   Regan, Ciaran M ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Cell cycle; IBMX; Isobutylmethyl xanthine; PDE; PDE4A; Phosphodiesterase; Restriction point; Teratogen; Valproate; VPA

Indexed keywords

CYCLIC AMP; ISOBUTYLMETHYLXANTHINE; PHOSPHODIESTERASE IV; VALPROIC ACID;

ANIMAL CELL; ARTICLE; CELL CYCLE G1 PHASE; CELL STRAIN; CHEMICAL TERATOGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; GLIOMA CELL; INTERMETHOD COMPARISON; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; UPREGULATION;

1-METHYL-3-ISOBUTYLXANTHINE; ADENOSINE TRIPHOSPHATE; ANIMALS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL MEMBRANE; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME ACTIVATION; ENZYME INHIBITORS; FORSKOLIN; G1 PHASE; GLIOMA; MICE; PHOSPHORIC DIESTER HYDROLASES; THYMIDINE; TIME FACTORS; TRITIUM; VALPROIC ACID;

EID: 1542375431     PISSN: 08920362     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ntt.2003.07.013     Document Type: Article

References (34)

1. Asghari V., Wang J.F., Reiach J.S., Young L.T. Differential effects of mood stabilizers on Fos/Jun proteins and AP-1 DNA binding activity in human neuroblastoma SH-SY5Y cells. Brain Res. Mol. Brain Res. 58:1998;95-102.
2. Axelrad A.A., McCulloch E.A. Obtaining suspensions of animal cells in metaphase from cultures propagated on glass. Stain Technol. 33:1957;67-71.
3. Bacon C.L., Gallagher H.C., Haughey J.C., Regan C.M. The anti-proliferative action of valproate is associated with aberrant expression and nuclear translocation of cyclin D3 during the C6 glioma G1 phase. J. Neurochem. 83:2002;12-19.
4. Bacon C.L., O'Driscoll E., Regan C.M. Valproic acid suppresses G1 phase-dependent sialylation of a 65 kDa glycoprotein in the C6 glioma cell cycle. Int. J. Dev. Neurosci. 15:1997;777-784.
5. Berezin V., Kawa A., Bojic U., Foley A., Nau H., Regan C.M., Bock E. Teratogenic potency of valproate analogues evaluated by quantitative estimation of cellular morphology in vitro. Toxicol. in vitro. 10:1996;585-594.
6. Bjerkedal T., Czeizel A., Goujard J., Kallen B., Mastoiacova P., Nevin N., Oakley G., Robert E. Valproic acid and spina bifida. Lancet. ii:1982;1096.
7. Bojic U., Ehlers K., Ellerbeck U., Bacon C.L., O'Driscoll E., O'Connell C., Berezin V., Kawa A., Lepekhin E., Bock E., Regan C.M., Nau H. Studies on the teratogen pharmacophore of valproic acid analogues: Evidence of interactions at a hydrophobic centre. Eur. J. Pharmacol. 354:1998;289-299.
8. Boonen G.J., van Oirschot B.A., van Diepen A., Mackus W.J., Verdonck L.F., Rijksen G., Medema R.H. Cyclin D3 regulates proliferation and apoptosis of leukemic T cell lines. J. Biol. Chem. 274:1999;34676-34682.
9. Brown B.L., Ekins R.P., Albano J.D. Saturation assay for cyclic AMP using endogenous binding protein. Adv. Cycl. Nucleotide Res. 2:1972;25-40.
10. Chen G., Hasanat K.A., Bebchuk J.M., Moore G.J., Glitz D., Manji H.K. Regulation of signal transduction pathways and gene expression by mood stabilizers and antidepressants. Psychosom. Med. 61:1999;599-617.
11. Chen G., Manji H.K., Hawver D.B., Wright C.B., Potter W.Z. Effects of valproic acid on beta-adrenergic receptors, G-proteins and adenylyl cyclase in rat C6 glioma cells. Neuropsychopharmacology. 15:1996;271-280.
12. Chen G., Yuan P., Hawver D.B., Potter W.Z., Manji H.K. Increase in AP-1 transcription factor DNA binding activity by valproic acid. Neuropsychopharmacology. 16:1997;238-245.
13. Courage-Maguire C., Bacon C.L., Nau H., Regan C.M. Correlation of in vitro anti-proliferative potential with in vivo teratogenicity in a series of valproate analogues. Int. J. Dev. Neurosci. 15:1997;37-43. Erratum 15 693-694.
14. Grdina D.J., Meistrich M.L., Meyn R.E., Johnson T.S., White R.A. Cell synchrony techniques: I. A comparison of methods. Cell Tissue Kinet. 17:1984;223-236.
15. Löscher W. Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog. Neurobiol. 58:1999;31-59.
16. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin reagent. J. Biol. Chem. 193:1951;265-275.
17. Manji H.K., Chen G. PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers. Mol. Psychiatry. 7(Suppl. 1):2002;S46-S56.
18. Manji H.K., Chen G., Hsiao J.K., Risby E.D., Masana M.I., Potter W.Z. Regulation of signal transduction pathways by mood-stabilizing agents: Implications for the delayed onset of therapeutic efficacy. J. Clin. Psychiatry. 57(Suppl. 13):1996;34-46.
19. Martin M.L., Breen K.C., Regan C.M. Perturbations of cellular functions integral to neural tube formation by the putative teratogen sodium valproate. Toxicol. In Vitro. 2:1988;43-48.
20. Martin M.L., Regan C.M. The anticonvulsant sodium valproate specifically induces the expression of a rat glial heat shock protein which is identified as the collagen type IV receptor. Brain Res. 459:1988;131-137.
21. Martin M.L., Regan C.M. The anticonvulsant valproate teratogen restricts the glial cell cycle at a defined point in the mid-G1 phase. Brain Res. 554:1991;223-228.
22. Murphy K.J., Fox G.B., Foley A.G., Gallagher H.C., O'Connell A., Griffin A.M., Nau H., Regan C.M. Pentyl-4-yn-valproic acid enhances both spatial and avoidance learning, and attenuates age-related NCAM-mediated neuroplastic decline within the rat medial temporal lobe. J. Neurochem. 784:2001;704-714.
23. O'Brien E., Regan C.M. Protein kinase C inhibitors arrest the C6 glioma cell cycle at a mid-G1 phase restriction point: Implications for the anti-proliferative action of valproate. Toxicol. In Vitro. 12:1998;9-14.
24. Pardee A.B. G1 events and regulation of cell proliferation. Science. 246:1989;603-608.
25. Post R.M., Weiss S.R., Chuang D.M. Mechanisms of action of anticonvulsants in affective disorders: Comparisons with lithium. J. Clin. Psychopharmacol. 12(Suppl. 1):1992;23S-35S.
26. Rasenick M.M., Chaney K.A., Chen J. G protein-mediated signal transduction as a target of antidepressant and antibipolar drug action: Evidence from model systems. J. Clin. Psychiatry. 57(Suppl. 13):1996;49-55.
27. Regan C.M. Therapeutic levels of sodium valproate inhibit mitotic indices in cells of neural origin. Brain Res. 347:1985;394-398.
28. Robert E., Guibaud P. Maternal valproic acid and congenital neural tube defects. Lancet. ii:1982;937.
29. Skladchikova G., Berezin V., Bock E. Valproic acid, but not its non-teratogenic analogue 2-isopropylpentanoic acid, affects proliferation, viability and neuronal differentiation of the human teratocarcinoma cell line Ntera-2. Neurotoxicology. 19:1998;357-370.
30. van Oirschot B.A., Stahl M., Lens S.M., Medema R.H. Protein kinase A regulates expression of p27(kip1) and cyclin D3 to suppress proliferation of leukemic T cell lines. J. Biol. Chem. 276:2001;33854-33860.
31. Walmod P.S., Berezin A., Gallagher H.C., Gravemann U., Lepekhin E.A., Belman V., Bacon C.L., Nau H., Regan C.M., Berezin V., Bock E. Automated in vitro screening of teratogens. Toxicol. Appl. Pharmacol. 181:2002;1-15.
32. Walmod P.S., Foley A., Berezin A., Ellerbeck U., Nau H., Bock E., Berezin V. Cell motility is inhibited by the antiepileptic compound, valproic acid and its teratogenic analogues. Cell Motil. Cytoskelet. 40:1998;220-237.
33. Wang J.F., Asghari V., Rockel C., Young L.T. Cyclic AMP responsive element binding protein phosphorylation and DNA binding is decreased by chronic lithium but not valproate treatment of SH-SY5Y neuroblastoma cells. Neuroscience. 91:1999;771-776.
34. Watterson J.M., Watson D.G., Meyer E.M., Lenox R.H. A role for protein kinase C and its substrates in the action of valproic acid in the brain: Implications for neural plasticity. Brain Res. 934:2002;69-80.